File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Conference Paper: A novel replication-competent modified vaccinia Tian Tan (MVTT) as a mucosal vaccination vehicle

TitleA novel replication-competent modified vaccinia Tian Tan (MVTT) as a mucosal vaccination vehicle
Authors
KeywordsMedical sciences
Communicable diseases medical sciences
Allergology and immunology
Issue Date2008
PublisherMary Ann Liebert, Inc Publishers. The Journal's web site is located at http://www.liebertpub.com/aid
Citation
The AIDS Vaccine 2008, Cape Town, South Africa, 13-16 October 2008. In AIDS Research and Human Retroviruses, 2008, v. 24, suppl. 1, p. 87, abstract no. P11-06 How to Cite?
AbstractBACKGROUND: Mucosal vaccination offers great advantage for inducing protective immune response at the sites of viral transmission. A novel replication-competent modified vaccinia Tian Tan (MVTT) is an attenuated variant of the wild-type VTT, which was historically used as a smallpox vaccine for millions of people in China. METHODS: MVTT was generated through genetic engineering and clonal selection of VTT. The spike glycoprotein (S) of SARS-CoV was used as the test antigen after the S gene was constructed in the identical genomic location of two live vectors to generate vaccine candidates MVTT-S and MVA-S. A head-to-head comparison has been conducted in mice for inducing neutralizing antibodies (Nabs) via mucosal vaccination. RESULTS: Using an identical dose, MVTT-S induced lower levels (2-fold) of Nabs than MVA-S after intramuscular (i.m.) inoculation. MVTT-S, however, was capable of inducing over 100-fold higher levels of Nabs than MVA-S when inoculated via either intranasal (i.n.) or intraoral (i.o.) routes. These levels of responses were higher (10-fold) than that induced via the i.m. route. Moreover, 2X10(6) PFU (20-fold) of MVA-S via i.n. or i.o. was required to achieve the level of Nab response induced by 105 PFU of MVTT-S via the same route. Pre-exposure to VTT via i.n. or i.o. route impaired the Nab response to S-glycoprotein through the same mucosal routes of MVTT-S vaccination. The impairment was likely due to the anti-vector Nab response inducied by VTT. CONCLUSION: Since the efficacy of mucosal vaccination was only slightly (2-fold) affected by pre-subcutaneous exposure of VTT, our findings have critical implications for people who maintain low levels of Nab after historical smallpox vaccination. MVTT is therefore an attractive vector for research of AIDS mucosal vaccination. The MVTT-SIVgpe vaccine is being studied in an SIV/macaque challenge model for inducing mucosal protection.
DescriptionPoster
Persistent Identifierhttp://hdl.handle.net/10722/62948
ISSN
2015 Impact Factor: 1.949
2015 SCImago Journal Rankings: 1.024

 

DC FieldValueLanguage
dc.contributor.authorChen, Zen_HK
dc.contributor.authorHuang, Xen_HK
dc.contributor.authorLu, B-
dc.contributor.authorFang, Q-
dc.contributor.authorYu, W-
dc.contributor.authorZhuang, K-
dc.contributor.authorTian, P-
dc.contributor.authorLiu, L-
dc.contributor.authorZhang, L-
dc.date.accessioned2010-07-13T04:12:43Z-
dc.date.available2010-07-13T04:12:43Z-
dc.date.issued2008en_HK
dc.identifier.citationThe AIDS Vaccine 2008, Cape Town, South Africa, 13-16 October 2008. In AIDS Research and Human Retroviruses, 2008, v. 24, suppl. 1, p. 87, abstract no. P11-06-
dc.identifier.issn0889-2229-
dc.identifier.urihttp://hdl.handle.net/10722/62948-
dc.descriptionPoster-
dc.description.abstractBACKGROUND: Mucosal vaccination offers great advantage for inducing protective immune response at the sites of viral transmission. A novel replication-competent modified vaccinia Tian Tan (MVTT) is an attenuated variant of the wild-type VTT, which was historically used as a smallpox vaccine for millions of people in China. METHODS: MVTT was generated through genetic engineering and clonal selection of VTT. The spike glycoprotein (S) of SARS-CoV was used as the test antigen after the S gene was constructed in the identical genomic location of two live vectors to generate vaccine candidates MVTT-S and MVA-S. A head-to-head comparison has been conducted in mice for inducing neutralizing antibodies (Nabs) via mucosal vaccination. RESULTS: Using an identical dose, MVTT-S induced lower levels (2-fold) of Nabs than MVA-S after intramuscular (i.m.) inoculation. MVTT-S, however, was capable of inducing over 100-fold higher levels of Nabs than MVA-S when inoculated via either intranasal (i.n.) or intraoral (i.o.) routes. These levels of responses were higher (10-fold) than that induced via the i.m. route. Moreover, 2X10(6) PFU (20-fold) of MVA-S via i.n. or i.o. was required to achieve the level of Nab response induced by 105 PFU of MVTT-S via the same route. Pre-exposure to VTT via i.n. or i.o. route impaired the Nab response to S-glycoprotein through the same mucosal routes of MVTT-S vaccination. The impairment was likely due to the anti-vector Nab response inducied by VTT. CONCLUSION: Since the efficacy of mucosal vaccination was only slightly (2-fold) affected by pre-subcutaneous exposure of VTT, our findings have critical implications for people who maintain low levels of Nab after historical smallpox vaccination. MVTT is therefore an attractive vector for research of AIDS mucosal vaccination. The MVTT-SIVgpe vaccine is being studied in an SIV/macaque challenge model for inducing mucosal protection.-
dc.languageengen_HK
dc.publisherMary Ann Liebert, Inc Publishers. The Journal's web site is located at http://www.liebertpub.com/aid-
dc.relation.ispartofAIDS Research and Human Retroviruses-
dc.subjectMedical sciences-
dc.subjectCommunicable diseases medical sciences-
dc.subjectAllergology and immunology-
dc.titleA novel replication-competent modified vaccinia Tian Tan (MVTT) as a mucosal vaccination vehicleen_HK
dc.typeConference_Paperen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0889-2229&volume=24, sippl. 1&spage=87&epage=&date=2008&atitle=A+novel+replication-competent+modified+vaccinia+Tian+Tan+(MVTT)+as+a+mucosal+vaccination+vehicle-
dc.identifier.emailChen, Z: zchenai@hkucc.hku.hken_HK
dc.identifier.emailLiu, L: lliuwhu@hotmail.comen_HK
dc.identifier.doi10.1089/aid.2008.9997a-
dc.identifier.hkuros165793en_HK
dc.identifier.volume24-
dc.identifier.issuesuppl. 1-
dc.identifier.spage87, abstract no. P11-06-
dc.identifier.epage87, abstract no. P11-06-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats